Advertisement

Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients

  • Mojdeh S. Heavner
  • Kimberly C. Claeys
  • Anne M. Masich
  • Jeffrey P. Gonzales
Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Healthcare Associated Infections

Abstract

Purpose of Review

We provide an overview of antimicrobials that are considered last resort for the treatment of resistant gram-negative infections in adult critically ill patients. The role in therapy, pharmacodynamic (PD) goals, and pharmacokinetic (PK) changes in critical illness for aminoglycosides, polymyxins, tigecycline, fosfomycin, and fluoroquinolones are summarized.

Recent Findings

Altered PK in septic patients in the intensive care unit (ICU) is observed with many of our agents of last resort. Based on the available literature, dosage adjustments may be required to optimize PK parameters and meet PD targets for most effective bacterial killing. Data is limited, studies are conducted in heterogeneous patient populations, and conclusions are frequently conflicting. Strategic dosing regimens such as high-dose extended interval dosing of aminoglycosides or loading doses with colistin and polymyxin B are examples of ways to optimize antibiotic PK in critically ill patients. Benefits of these strategies must be balanced with risks of increased toxicity.

Summary

Patients with resistant gram-negative infections may present with septic shock in the ICU. Sepsis can significantly alter the PK of antibiotics and require dosage adjustments to attain optimal drug levels. An understanding of PK and PD properties of these agents of last resort will help to maximize therapeutic efficacy while minimizing toxic effects.

Keywords

Aminoglycosides Polymyxins Tigecycline Fosfomycin Fluoroquinolones ICU 

Notes

Compliance with Ethical Standards

Conflict of Interest

Anne M. Masich, Mojdeh S. Heavner, Jeffrey P. Gonzales, and Kimberly C. Claeys declare they have no conflicts of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2013–2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. Microb Drug Resist. 2017.Google Scholar
  3. 3.
    van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2017.Google Scholar
  4. 4.
    Rodriguez-Avial I, Pena I, Picazo JJ, Rodriguez-Avial C, Culebras E. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46(6):616–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017.Google Scholar
  6. 6.
    Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Hobbs AL, Shea KM, Roberts KM, Daley MJ. Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics. Pharmacotherapy. 2015;35(11):1063–75.CrossRefPubMedGoogle Scholar
  8. 8.
    Eyler RF, Mueller BA, Medscape. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2011;7(4):226–35.CrossRefPubMedGoogle Scholar
  9. 9.
    Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110.CrossRefPubMedGoogle Scholar
  10. 10.
    • Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med. 2014;42(7):1640–50. Analysis of PK data from 30 studies to determine the effects of renal replacement modalities on clearance of beta-lactam antibiotics.CrossRefPubMedGoogle Scholar
  11. 11.
    Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature. Clin Ther. 2016;38(9):1976–94.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Radigan EA, Gilchrist NA, Miller MA. Management of aminoglycosides in the intensive care unit. J Intensive Care Med. 2010;25(6):327–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16(5):303–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Tholl DA, Shikuma LR, Miller TQ, Woodward JM, Cerra FB, Zaske DE. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med. 1993;21(2):248–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Barletta JF, Johnson SB, Nix DE, Nix LC, Erstad BL. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma. 2000;49(5):869–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984;149(3):443–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55(6):2528–31.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986;5(4):319–24.PubMedGoogle Scholar
  20. 20.
    Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43(3):623–9.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med. 2007;28(6):596–603.CrossRefPubMedGoogle Scholar
  22. 22.
    Urban AW, Craig WA. Daily dosage of aminoglycosides. Curr Clin Top Infect Dis. 1997;17:236–55.PubMedGoogle Scholar
  23. 23.
    Agence francaise de securite sanitaire des produits de s. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect 2012;42(7):301–8.Google Scholar
  24. 24.
    Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm. 1996;53(10):1141–50.PubMedGoogle Scholar
  25. 25.
    Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. 2014;40(7):998–1005.CrossRefPubMedGoogle Scholar
  27. 27.
    Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38(2):146–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Roger C, Nucci B, Molinari N, Bastide S, Saissi G, Pradel G, et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents. 2015;46(1):21–7.CrossRefPubMedGoogle Scholar
  29. 29.
    • Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71(1):208–12. Study to assess PK/PD target attainment in critically ill patients in the ICU using higher doses of aminoglycoside; 94% achieved PK/PD target by available MIC however second dose often withheld.CrossRefPubMedGoogle Scholar
  30. 30.
    Bacopoulou F, Markantonis SL, Pavlou E, Adamidou M. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care. 2003;18(2):107–13.CrossRefPubMedGoogle Scholar
  31. 31.
    Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother. 2006;40(1):9–14.CrossRefPubMedGoogle Scholar
  32. 32.
    Halpren BA, Axline SG, Coplon NS, Brown DM. Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. J Infect Dis. 1976;133(6):627–36.CrossRefPubMedGoogle Scholar
  33. 33.
    Kaye D, Levison ME, Labovitz ED. The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function. J Infect Dis. 1974;130(2):150–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159–66.CrossRefPubMedGoogle Scholar
  35. 35.
    Taccone FS, de Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2011;37(6):531–5.CrossRefPubMedGoogle Scholar
  36. 36.
    • Gelisse E, Neuville M, de Montmollin E, Bouadma L, Mourvillier B, Timsit JF, et al. Extracorporeal membrane oxygenation (ECMO) does not impact on amikacin pharmacokinetics: a case-control study. Intensive Care Med. 2016;42(5):946–8. Letter to the editor providing observational single-center data comparing amikacin levels in patients on ECMO to those not receiving ECMO demonstrating no significant differences in doses or peak levels achieved.CrossRefPubMedGoogle Scholar
  37. 37.
    Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther. 2011;89(6):875–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Gregoire N, Aranzana-Climent V, Magreault S, Marchand S, Couet W. Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin Pharmacokinet. 2017.Google Scholar
  39. 39.
    Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47(10):1298–304.CrossRefPubMedGoogle Scholar
  40. 40.
    Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–31.CrossRefPubMedGoogle Scholar
  41. 41.
    Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;38(11):1779–86.CrossRefPubMedGoogle Scholar
  42. 42.
    Boisson M, Jacobs M, Gregoire N, Gobin P, Marchand S, Couet W, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331–9.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Gregoire N, Mimoz O, Megarbane B, Comets E, Chatelier D, Lasocki S, et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother. 2014;58(12):7324–30.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Karnik ND, Sridharan K, Jadhav SP, Kadam PP, Naidu RK, Namjoshi RD, et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. Eur J Clin Pharmacol. 2013;69(7):1429–36.CrossRefPubMedGoogle Scholar
  46. 46.
    • Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother. 2015;59(12):7240–8. Pharmacokinetic study of 19 critically ill patients that received loading doses of 9 MU colistin methanesulfonate demonstrating levels greater than 2 mg/liter within hours of administration.CrossRefPubMedCentralPubMedGoogle Scholar
  47. 47.
    Elefritz JL, Bauer KA, Jones C, Mangino JE, Porter K, Murphy CV. Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant gram-negative pneumonia. J Intensive Care Med. 2017;32(8):487–93.CrossRefPubMedGoogle Scholar
  48. 48.
    Rigatto MH, Oliveira MS, Perdigao-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–9.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Jacobs M, Gregoire N, Megarbane B, Gobin P, Balayn D, Marchand S, et al. Population pharmacokinetics of colistin methanesulfonate and colistin in critically ill patients with acute renal failure requiring intermittent hemodialysis. Antimicrob Agents Chemother. 2016;60(3):1788–93.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    • Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013;57(1):668–71. Pharmacokinetic study of 5 critically ill patients receiving colistin methanesulfonate also receiving continuous venovenous hemodiafiltration.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant acinetobacter baumannii pneumonia in critically ill patients. PLoS One. 2016;11(3):e0150642.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194–204.CrossRefPubMedGoogle Scholar
  54. 54.
    Metan G, Alp E, Yildiz O, Percin D, Aygen B, Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant acinetobacter infections. J Chemother. 2010;22(2):110–4.CrossRefPubMedGoogle Scholar
  55. 55.
    Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant acinetobacter baumannii. Pharmacotherapy. 2007;27(7):980–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47(2):107–16.CrossRefPubMedGoogle Scholar
  57. 57.
    Ni W, Han Y, Liu J, Wei C, Zhao J, Cui J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(11):e3126.CrossRefGoogle Scholar
  58. 58.
    He H, Zheng Y, Sun B, Tang X, Wang R, Tong Z. Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant acinetobacter baumannii. J Thorac Dis. 2016;8(10):2784–92.CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Amat T, Gutierrez-Pizarraya A, Machuca I, Gracia-Ahufinger I, Perez-Nadales E, Torre-Gimenez A, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant acinetobacter baumannii. Clin Microbiol Infect. 2017.Google Scholar
  60. 60.
    • Xie J, Roberts JA, Alobaid AS, Roger C, Wang Y, Yang Q, et al. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Antimicrob Agents Chemother. 2017;61(8). Population pharmacokinetic and Monto Carlo simulation to describe the kinetics of tigecycline in critically ill adults demonstrated that approved doses may be insufficient to reach PK/PD targets.Google Scholar
  61. 61.
    Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52(1):204–10.CrossRefPubMedGoogle Scholar
  62. 62.
    Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065–72.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51(6):1939–45.CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.
    D I. Analysis of an increase in all-cause mortality in tigecycline treated patients. ICAAC 2011;Abstract K-1428.Google Scholar
  65. 65.
    Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, et al. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Int J Antimicrob Agents. 2010;36(2):137–44.CrossRefPubMedGoogle Scholar
  66. 66.
    Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756–62.CrossRefPubMedCentralPubMedGoogle Scholar
  67. 67.
    Xu L, Wang YL, Du S, Chen L, Long LH, Wu Y. Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61(6):323–30.CrossRefPubMedGoogle Scholar
  68. 68.
    Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220–9.CrossRefPubMedCentralPubMedGoogle Scholar
  70. 70.
    Dixit D, Madduri RP, Sharma R. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti-Infect Ther. 2014;12(4):397–400.CrossRefPubMedGoogle Scholar
  71. 71.
    Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069–77.CrossRefPubMedGoogle Scholar
  73. 73.
    Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection. 1990;18(Suppl 2):S65–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016;22(5):273–80.CrossRefPubMedCentralPubMedGoogle Scholar
  75. 75.
    Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637–56.CrossRefPubMedGoogle Scholar
  76. 76.
    Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34(6):506–15.CrossRefPubMedGoogle Scholar
  77. 77.
    Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents. 2013;42(4):289–93.CrossRefPubMedGoogle Scholar
  78. 78.
    Borsa F, Leroy A, Fillastre JP, Godin M, Moulin B. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrob Agents Chemother. 1988;32(6):938–41.CrossRefPubMedCentralPubMedGoogle Scholar
  79. 79.
    • Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D, et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother. 2015;59(10):6471–6. Population pharmacokinetic study of intravenous fosfomycin in critically ill patients.CrossRefPubMedCentralPubMedGoogle Scholar
  80. 80.
    Albur MS, Noel A, Bowker K, MacGowan A. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents. 2015;46(5):560–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Inouye S, Niizato T, Takeda U, Koeda T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. Aust J Pharm. 1982;5(9):659–69.Google Scholar
  82. 82.
    Yoshiyama Y, Yazaki T, Wong PC, Beauchamp D, Kanke M. The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats. J Infect Chemother. 2001;7(4):243–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Kreft B, de Wit C, Marre R, Sack K. Experimental studies on the nephrotoxicity of amphotericin B in rats. J Antimicrob Chemother. 1991;28(2):271–81.CrossRefPubMedGoogle Scholar
  84. 84.
    Asuphon O, Montakantikul P, Houngsaitong J, Kiratisin P, Sonthisombat P. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. Int J Infect Dis. 2016;50:23–9.CrossRefPubMedGoogle Scholar
  85. 85.
    Schmidt JJ, Bode-Boger SM, Wilhelmi M, Omar M, Martens-Lobenhoffer J, Welte T, et al. Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing. J Antimicrob Chemother. 2016;71(9):2673–4.CrossRefPubMedGoogle Scholar
  86. 86.
    Gattringer R, Meyer B, Heinz G, Guttmann C, Zeitlinger M, Joukhadar C, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2006;58(2):367–71.CrossRefPubMedGoogle Scholar
  87. 87.
    Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother. 2003;51(5):1247–52.CrossRefPubMedGoogle Scholar
  88. 88.
    Frossard M, Joukhadar C, Erovic BM, Dittrich P, Mrass PE, Van Houte M, et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother. 2000;44(10):2728–32.CrossRefPubMedCentralPubMedGoogle Scholar
  89. 89.
    Dalet F, Bade G, Roda M. Pharmacokinetics of fosfomycin during hemodialysis. Chemotherapy. 1977;23(Suppl 1):210–6.CrossRefPubMedGoogle Scholar
  90. 90.
    • Grabein B, Graninger W, Rodriguez Bano J, Dinh A, Liesenfeld DB. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23(6):363–72. Systematic review and meta-analysis of 128 studies of intravenous fosfomycin demonstrating no difference in clinical outcomes or efficacy in relation to comparator antibiotics.CrossRefPubMedGoogle Scholar
  91. 91.
    Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289(7):885–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Paiva JA, Pereira JM. Fluoroquinolones: another line in the long list of their collateral damage record. Crit Care Med. 2015;43(3):708–10.CrossRefPubMedGoogle Scholar
  93. 93.
    • Roberts JA, Cotta MO, Cojutti P, Lugano M, Della Rocca G, Pea F. Does critical illness change levofloxacin pharmacokinetics? Antimicrob Agents Chemother. 2015;60(3):1459–63. Pharmacokinetic study of alterations in levofloxacin kinetics in critically ill adults stating that critical illness has no apparent effect beyond changes in renal function.CrossRefPubMedGoogle Scholar
  94. 94.
    Conil JM, Georges B, de Lussy A, Khachman D, Seguin T, Ruiz S, et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents. 2008;32(6):505–10.CrossRefPubMedGoogle Scholar
  95. 95.
    Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002;22(10):1216–25.CrossRefPubMedGoogle Scholar
  96. 96.
    Kees MG, Schaeftlein A, Haeberle HA, Kees F, Kloft C, Heininger A. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. J Antimicrob Chemother. 2013;68(6):1331–7.CrossRefPubMedGoogle Scholar
  97. 97.
    Szalek E, Tomczak H, Kaminska A, Grabowski T, Smuszkiewicz P, Matysiak K, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg. Adv Med Sci. 2012;57(2):217–23.CrossRefPubMedGoogle Scholar
  98. 98.
    Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27(1):19–34.CrossRefPubMedGoogle Scholar
  99. 99.
    Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073–81.CrossRefPubMedCentralPubMedGoogle Scholar
  100. 100.
    Shotwell MS, Madonia PN, Connor MJ, Amde M, Salem C, Aduroja OA, et al. Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis. Am J Kidney Dis. 2015;66(1):173–5.CrossRefPubMedGoogle Scholar
  101. 101.
    • Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, et al. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. J Antimicrob Chemother. 2016;71(6):1643–50. Pharmacokinetic study examining changes in ciprofloxacin kinetics based on renal replacement modality found no significant differences between CVVHF and CVVHDF.CrossRefPubMedGoogle Scholar
  102. 102.
    Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, et al. Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med. 2015;43(3):594–602.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Mojdeh S. Heavner
    • 1
  • Kimberly C. Claeys
    • 1
  • Anne M. Masich
    • 1
  • Jeffrey P. Gonzales
    • 1
  1. 1.Department of Pharmacy Practice and ScienceUniversity of Maryland School of PharmacyBaltimoreUSA

Personalised recommendations